A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

NCT07241390 · Recruiting

Last updated 2026-05-28

This study is testing whether the medication orforglipron (LY3502970) can help reduce major cardiovascular events in adults who already have heart disease and/or kidney disease.

Status Recruiting Currently enrolling participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 7,140 people Planned (estimated).

Who can join Ages 50+ · all sexes

Timeline Started 2025-12 · est. completion 2031-08

Where 568 sites · Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Czechia, Estonia, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Philippines, Poland, Romania, Serbia, Slovakia, South Africa, South Korea, Spain, Taiwan, Thailand, Tunisia, Turkey (Türkiye), Ukraine, United Kingdom

What this study is testing ClinicalTrials.gov NCT07241390 ↗

Description as written by the study sponsor.

The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.

Treatments tested

Orforglipron also known as LY3502970 Drug

Administered orally
Placebo Drug

Administered orally

Main thing measured	Time to First Occurrence of Composite Endpoint of Major Cardiovascular Events
Sponsor	Eli Lilly and Company
Conditions studied	Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease
GLP-1 drugs	orforglipron

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07241390 ↗